Commentary on: Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.
International Society of Chemotherapy Antimicrobial Stewardship Working Group, Hospital Carlos G. Durand, Buenos Aires, Argentina. glevyhara@fibertel.com.ar
Gabriel Levy
GL
Hara
D017714:Community-Acquired Infections / Q000188:drug therapy*; D024901:Drug Resistance, Multiple, Bacterial; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000472:pathogenicity*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D024841:Fluoroquinolones